The aim of this study was to evaluate maternal serum soluble urokinase plasminogen activator receptor levels in pregnant women with preterm premature rupture of membranes and to determine the predictive value in neonatal outcomes.<h4>Methods</h4>In this prospective case-control study, complete blood count parameters, serum C-reactive protein, and soluble urokinase plasminogen activator receptor levels of 40 pregnant women with preterm premature rupture of membranes and 40 randomly selected healthy pregnant women between 22 and 34 weeks' gestation were recorded. The gene discussed is PLAUR; the disease is Premature rupture of membranes.